vs
Side-by-side financial comparison of Twist Bioscience Corp (TWST) and Vitesse Energy, Inc. (VTS). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $58.6M, roughly 1.8× Vitesse Energy, Inc.). Vitesse Energy, Inc. runs the higher net margin — -1.3% vs -29.4%, a 28.2% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 4.8%).
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
Vitesse Energy, Inc. is a U.S.-headquartered independent energy company focused on exploration, development, and production of oil and natural gas assets. It operates primarily in high-potential onshore basins including North Dakota's Williston Basin, serving domestic and global upstream energy market demand.
TWST vs VTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $103.7M | $58.6M |
| Net Profit | $-30.5M | $-739.0K |
| Gross Margin | 52.0% | — |
| Operating Margin | -31.7% | -12.0% |
| Net Margin | -29.4% | -1.3% |
| Revenue YoY | 16.9% | 4.8% |
| Net Profit YoY | 3.4% | 85.6% |
| EPS (diluted) | $-0.50 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $103.7M | $58.6M | ||
| Q3 25 | — | $67.4M | ||
| Q2 25 | — | $81.8M | ||
| Q1 25 | — | $66.2M | ||
| Q4 24 | — | $55.9M | ||
| Q3 24 | — | $58.3M | ||
| Q2 24 | — | $66.6M | ||
| Q1 24 | — | $61.2M |
| Q4 25 | $-30.5M | $-739.0K | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | $24.7M | ||
| Q1 25 | — | $2.7M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $17.4M | ||
| Q2 24 | — | $10.9M | ||
| Q1 24 | — | $-2.2M |
| Q4 25 | 52.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -31.7% | -12.0% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 22.8% | ||
| Q1 25 | — | 8.1% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | — | 15.4% | ||
| Q2 24 | — | 25.2% | ||
| Q1 24 | — | 21.4% |
| Q4 25 | -29.4% | -1.3% | ||
| Q3 25 | — | -1.9% | ||
| Q2 25 | — | 30.2% | ||
| Q1 25 | — | 4.0% | ||
| Q4 24 | — | -9.2% | ||
| Q3 24 | — | 29.9% | ||
| Q2 24 | — | 16.4% | ||
| Q1 24 | — | -3.6% |
| Q4 25 | $-0.50 | $-0.01 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $0.60 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | — | $0.53 | ||
| Q2 24 | — | $0.33 | ||
| Q1 24 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $197.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $456.1M | $629.3M |
| Total Assets | $638.1M | $893.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $197.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $4.5M | ||
| Q4 24 | — | $3.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $456.1M | $629.3M | ||
| Q3 25 | — | $650.3M | ||
| Q2 25 | — | $671.9M | ||
| Q1 25 | — | $667.7M | ||
| Q4 24 | — | $500.3M | ||
| Q3 24 | — | $520.4M | ||
| Q2 24 | — | $518.5M | ||
| Q1 24 | — | $522.7M |
| Q4 25 | $638.1M | $893.4M | ||
| Q3 25 | — | $932.9M | ||
| Q2 25 | — | $951.5M | ||
| Q1 25 | — | $975.2M | ||
| Q4 24 | — | $810.9M | ||
| Q3 24 | — | $791.2M | ||
| Q2 24 | — | $778.4M | ||
| Q1 24 | — | $749.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-24.8M | $37.4M |
| Free Cash FlowOCF − Capex | $-34.8M | — |
| FCF MarginFCF / Revenue | -33.5% | — |
| Capex IntensityCapex / Revenue | 9.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-24.8M | $37.4M | ||
| Q3 25 | — | $49.4M | ||
| Q2 25 | — | $66.0M | ||
| Q1 25 | — | $17.5M | ||
| Q4 24 | — | $34.7M | ||
| Q3 24 | — | $45.7M | ||
| Q2 24 | — | $35.2M | ||
| Q1 24 | — | $39.4M |
| Q4 25 | $-34.8M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -33.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 9.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.68× | ||
| Q1 25 | — | 6.56× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.62× | ||
| Q2 24 | — | 3.22× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
VTS
| Oil Reserves | $54.5M | 93% |
| Natural Gas Reserves | $4.2M | 7% |
